The University of Chicago Header Logo

Connection

Ravi Salgia to ErbB Receptors

Back to Details
This is a "connection" page, showing publications Ravi Salgia has written about ErbB Receptors.
Ravi Salgia
Connection Strength
4.312
ErbB Receptors
  1. Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy. BMC Cancer. 2018 03 21; 18(1):314.
    View in: PubMed
    Score: 0.442
  2. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One. 2010 Jan 29; 5(1):e8972.
    View in: PubMed
    Score: 0.252
  3. MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. J Environ Pathol Toxicol Oncol. 2009; 28(2):89-98.
    View in: PubMed
    Score: 0.234
  4. EGFR-targeted therapeutics: focus on SCCHN and NSCLC. ScientificWorldJournal. 2008 Sep 21; 8:909-19.
    View in: PubMed
    Score: 0.229
  5. Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res. 2006 Dec 15; 12(24):7261-70.
    View in: PubMed
    Score: 0.203
  6. Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology. 2006 Nov; 11(6):687-92.
    View in: PubMed
    Score: 0.201
  7. Current paradigm of EGFRins20 in non-small cell lung cancer: A long way forward. Med. 2025 Sep 12; 6(9):100803.
    View in: PubMed
    Score: 0.185
  8. Novel therapies in lung cancer. Hematol Oncol Clin North Am. 2005 Apr; 19(2):343-67, vii.
    View in: PubMed
    Score: 0.180
  9. Targeted Therapies in Early-Stage Resectable Non-Small-Cell Lung Cancer: New Kids on the Block. JCO Precis Oncol. 2023 Sep; 7:e2200445.
    View in: PubMed
    Score: 0.161
  10. Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor. J Clin Oncol. 2023 02 10; 41(5):1129-1131.
    View in: PubMed
    Score: 0.152
  11. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Chest. 2021 09; 160(3):1095-1107.
    View in: PubMed
    Score: 0.137
  12. Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases. Magn Reson Imaging. 2020 06; 69:49-56.
    View in: PubMed
    Score: 0.127
  13. Precision medicine and actionable alterations in lung cancer: A single institution experience. PLoS One. 2020; 15(2):e0228188.
    View in: PubMed
    Score: 0.126
  14. Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. Sci Rep. 2017 08 23; 7(1):9192.
    View in: PubMed
    Score: 0.106
  15. RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor. Sci Signal. 2017 01 03; 10(460).
    View in: PubMed
    Score: 0.102
  16. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget. 2016 Oct 11; 7(41):66880-66891.
    View in: PubMed
    Score: 0.100
  17. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Lett. 2016 10 01; 380(2):494-504.
    View in: PubMed
    Score: 0.099
  18. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. Mol Cancer Ther. 2016 09; 15(9):2175-86.
    View in: PubMed
    Score: 0.098
  19. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. Mol Cancer Ther. 2014 May; 13(5):1356-68.
    View in: PubMed
    Score: 0.084
  20. Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer. 2013 Jul; 81(1):138-41.
    View in: PubMed
    Score: 0.079
  21. Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. J Thorac Oncol. 2012 May; 7(5):856-65.
    View in: PubMed
    Score: 0.074
  22. A novel classification of lung cancer into molecular subtypes. PLoS One. 2012; 7(2):e31906.
    View in: PubMed
    Score: 0.073
  23. Personalized treatment of lung cancer. Semin Oncol. 2011 Apr; 38(2):274-83.
    View in: PubMed
    Score: 0.068
  24. Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res. 2011 Apr 01; 71(7):2423-7.
    View in: PubMed
    Score: 0.067
  25. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist. 2009 Nov; 14(11):1116-30.
    View in: PubMed
    Score: 0.062
  26. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5714-23.
    View in: PubMed
    Score: 0.061
  27. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31.
    View in: PubMed
    Score: 0.059
  28. Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity. Oncogene. 2009 Jan 29; 28(4):518-33.
    View in: PubMed
    Score: 0.058
  29. Tyrosine kinase mutations in human cancer. Curr Mol Med. 2007 Feb; 7(1):77-84.
    View in: PubMed
    Score: 0.051
  30. Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat Clin Pract Oncol. 2006 Jan; 3(1):50-7; quiz 1 p following 57.
    View in: PubMed
    Score: 0.047
  31. Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024. Cancer. 2025 Sep 01; 131(17):e70060.
    View in: PubMed
    Score: 0.046
  32. Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer. 2023 04; 178:166-171.
    View in: PubMed
    Score: 0.039
  33. Role of receptor tyrosine kinases in lung cancer. Methods Mol Med. 2003; 74:113-25.
    View in: PubMed
    Score: 0.039
  34. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002 Sep 15; 62(18):5242-7.
    View in: PubMed
    Score: 0.038
  35. AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer. BMC Cancer. 2022 Apr 23; 22(1):447.
    View in: PubMed
    Score: 0.037
  36. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. J Thorac Oncol. 2021 06; 16(6):1030-1041.
    View in: PubMed
    Score: 0.034
  37. Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem. 2000 Mar 10; 275(10):6868-75.
    View in: PubMed
    Score: 0.032
  38. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 01; 21(19):4321-6.
    View in: PubMed
    Score: 0.023
  39. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer. 2014 Oct 24; 13:242.
    View in: PubMed
    Score: 0.022
  40. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One. 2014; 9(3):e91577.
    View in: PubMed
    Score: 0.021
  41. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5.
    View in: PubMed
    Score: 0.021
  42. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011 Dec 20; 29(36):4803-10.
    View in: PubMed
    Score: 0.018
  43. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
    View in: PubMed
    Score: 0.014
  44. Key signaling pathways and targets in lung cancer therapy. Clin Lung Cancer. 2007 Feb; 8 Suppl 2:S52-60.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.